This open-label , phase II study randomized patients with HER2-positive stage II or III invasive breast cancer to trastuzumab , lapatinib , or both , 2 weeks prior to and during chemotherapy with FEC75 for 4 courses ; then paclitaxel 80 mg/m2 weekly for 12 courses , then surgery .